22 results about "Sperm protein" patented technology

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

This disclosure relates to homodimeric antibodies for use in treating cancer generally and to both homodimeric antibodies that bind human sperm protein 17 (Sp17) and homodimeric antibody immunoconjugates specifically. Such homodimeric antibodies display improved properties relative to monomeric antibodies, for example, because they can crosslink cells, improve cellular uptake, and / or carry greater payloads.

This disclosure relates to dimeric immunoconjugates for use in treating cancer generally and to dimeric immunoconjugates that bind human sperm protein 17 (Sp17) specifically. A dimeric immunoconjugate of this disclosure generally comprises a first monomeric antibody that carries a first payload and a second monomeric antibody that carries a second payload, wherein the first payload and the second payload are different. Such dimeric immunoconjugates advantageously allow the simultaneous delivery of two chemotherapeutics to a cancer cell, which allows for synergistic antineoplastic activity.

This disclosure relates to homodimeric antibodies for use in treating cancer generally and to both homodimeric antibodies that bind human sperm protein 17 (Sp17) and homodimeric antibody immunoconjugates specifically. Such homodimeric antibodies display improved properties relative to monomeric antibodies, for example, because they can crosslink cells, improve cellular uptake, and / or carry greater payloads.

The application relates to the technical field of biological medicine, and discloses a drug composition containing nuclear autoantigen sperm protein for promoting myocardial regeneration and repair and application, which comprises an NASP gene; the nucleotide sequence of the NASP gene is shown as SEQ ID NO:1, and the amino acid sequence encoded by the NASP gene is shown as SEQ ID NO:2. The drug composition can promote the number of myocardial cells, repair the necrotic myocardium, and thus improve acute myocardial infarction at the gene level.

The present disclosure describes proteins that specifically bind to human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include recombinant human anti-Sp17 IgG, which are suitable for use as therapeutic antibodies to treat cancers that express Sp17 ectopic. Other Sp17 binding proteins, including antibody fragments, antibody conjugates, and fusion proteins, are also described.

The invention discloses a pentapeptide YP5 with a function of relieving diabetic kidney injury as well as a preparation method and application of the pentapeptide YP5, and belongs to the technical field of biology. The pentapeptide YP5 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is YVAAP, and the pentapeptide YP5 has the function of relieving the diabetic kidney injury, can remarkably reduce the content of fasting blood-glucose, serum creatinine, urea nitrogen and urine protein of diabetic mice, has better activity and smaller toxic and side effects than a positive drug metformin, and can be used for preparing the medicine for treating diabetic kidney injury. The method can be applied to functional food for relieving diabetic kidney injury.

This disclosure relates to homodimeric antibodies for use in treating cancer generally and to both homodimeric antibodies that bind human sperm protein 17 (Sp17) and homodimeric antibody immunoconjugates specifically. Such homodimeric antibodies display improved properties relative to monomeric antibodies, for example, because they can crosslink cells, improve cellular uptake, and / or carry greater payloads.

The invention provides an anti-human sperm SP10 protein monoclonal antibody pairing combination and application thereof. The anti-human sperm SP10 protein monoclonal antibody pairing combination comprises anti-human sperm SP10 protein monoclonal antibodies Ab1 and Ab2; amino acid sequences of a heavy chain CDR1 sequence, a CDR2 sequence and a CDR3 sequence of the monoclonal antibody Ab1 are shown as SEQ ID NO: 2-4, and amino acid sequences of a light chain CDR1 sequence, a CDR2 sequence and a CDR3 sequence of the monoclonal antibody Ab1 are shown as SEQ ID NO: 6-8; the amino acid sequences of a heavy chain CDR1 sequence, a CDR2 sequence and a CDR3 sequence of the monoclonal antibody Ab2 are as shown in SEQ ID NO: 10-12, and the amino acid sequences of a light chain CDR1 sequence, a CDR2 sequence and a CDR3 sequence of the monoclonal antibody Ab2 are as shown in SEQ ID NO: 14-16. The pair has the characteristics of high affinity and high specificity.

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

The application discloses a sperm protein marker LYPD4 closely related to human sperm hyperactivation movement and an application thereof, and belongs to the technical field of biology.The application first proves that the LYPD4 protein is closely related to human sperm hyperactivation movement, and the relative content of the LYPD4 protein is significantly positively correlated with the human sperm hyperactivation rate; the LYPD4 antibody can significantly inhibit the total activity, forward movement, hyperactivation movement, penetration mucus capacity and sperm capacitation level of human sperm.The application provides a new application of the LYPD4 as a sperm function evaluation biomarker, and can be used for preparing a human sperm hyperactivation capacity detection kit, screening high-quality sperm for assisted reproduction, male infertility diagnosis and therapeutic drugs.The application fills a research blank of specific molecular markers of sperm hyperactivation movement, provides a new target and a new method for male reproductive health diagnosis and treatment and assisted reproduction technology, and has important scientific research value and clinical application prospect.

This disclosure relates to dimeric immunoconjugates for use in treating cancer generally and to dimeric immunoconjugates that bind human sperm protein 17 (Sp17) specifically. A dimeric immunoconjugate of this disclosure generally comprises a first monomeric antibody that carries a first payload and a second monomeric antibody that carries a second payload, wherein the first payload and the second payload are different. Such dimeric immunoconjugates advantageously allow the simultaneous delivery of two chemotherapeutics to a cancer cell, which allows for synergistic antineoplastic activity.

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

The invention discloses an application of FXYD1 protein in sperm centromere detection. The amino acid sequence of the FXYD1 protein is as shown in SEQ ID NO. 1. By identifying an antibody of the FXYD1 protein, the expression position of the FXYD1 protein on the sperm is marked, and the number and position of centromere in the sperm are analyzed by combining immunostaining and microscope observation. The method can effectively evaluate the sperm centromere structure state, including existence, number and position form of centromere; the related expression of the sperm FXYD1 protein can also be evaluated. The human sperm quality evaluation method provided by the invention is helpful for objectively judging sperm functions, embryonic development after fertilization, physiological and pathological states related to male fertility and prognosis results of the physiological and pathological states, and has important transformation and popularization values and wide application prospects in the fields of reproductive biology and reproductive medicine.

The invention relates to the technical field of biological medicines, and discloses a nuclear autoantigen sperm protein-containing pharmaceutical composition for promoting myocardial regeneration and repair and application of the nuclear autoantigen sperm protein-containing pharmaceutical composition. The nucleotide sequence of the NASP gene is as shown in SEQ ID NO: 1, and the coded amino acid sequence of the NASP gene is as shown in SEQ ID NO: 2. The pharmaceutical composition disclosed by the invention can promote the number of myocardial cells and repair necrotic myocardium on the gene level, so that acute myocardial infarction is improved.

The present invention discloses a hexapeptide VA6 with anti-fatigue function, as well as its preparation method and application, belonging to the field of biotechnology. The hexapeptide VA6, screened from Pacific salmon sperm protein hydrolysate, has an amino acid sequence of VGVVVA and strong binding ability to AMPK and LDH. It can significantly increase the liver glycogen content and significantly reduce the serum urea nitrogen content in fatigue model mice, alleviate the fatigue phenotype of fatigue model mice, and significantly increase the weighted swimming time of fatigue model mice. It has anti-fatigue function and can be used in the development of functional foods that relieve fatigue.

The present disclosure describes proteins that specifically bind to human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include recombinant human anti-Sp17 IgG, which are suitable for use as therapeutic antibodies to treat cancers that express Sp17 ectopic. Other Sp17 binding proteins, including antibody fragments, antibody conjugates, and fusion proteins, are also described.

The present disclosure describes proteins that specifically bind to human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include recombinant human anti-Sp17 IgG, which are suitable for use as therapeutic antibodies to treat cancers that express Sp17 ectopic. Other Sp17 binding proteins, including antibody fragments, antibody conjugates, and fusion proteins, are also described.

This disclosure relates to dimeric immunoconjugates for use in treating cancer generally and to dimeric immunoconjugates that bind human sperm protein 17 (Sp17) specifically. A dimeric immunoconjugate of this disclosure generally comprises a first monomeric antibody that carries a first payload and a second monomeric antibody that carries a second payload, wherein the first payload and the second payload are different. Such dimeric immunoconjugates advantageously allow the simultaneous delivery of two chemotherapeutics to a cancer cell, which allows for synergistic antineoplastic activity.

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

The application provides a pair of anti-human sperm SP10 protein monoclonal antibody combinations and application thereof, comprising anti-human sperm SP10 protein monoclonal antibodies Ab1 and Ab2; the amino acid sequences of the heavy chain CDR1 sequence, the CDR2 sequence and the CDR3 sequence of the monoclonal antibody Ab1 are shown in SEQ ID NO:2-4, the amino acid sequences of the light chain CDR1 sequence, the CDR2 sequence and the CDR3 sequence are shown in SEQ ID NO:6-8; the amino acid sequences of the heavy chain CDR1 sequence, the CDR2 sequence and the CDR3 sequence of the monoclonal antibody Ab2 are shown in SEQ ID NO:10-12, and the amino acid sequences of the light chain CDR1 sequence, the CDR2 sequence and the CDR3 sequence are shown in SEQ ID NO:14-16. The pair has the characteristics of high affinity and high specificity.